Your browser doesn't support javascript.
loading
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia, Wenle; Liu, Zuguo; Zong, Rongrong; Liu, Leihua; Zhao, Sumin; Bacus, Sarah S; Mao, Yubin; He, Jia; Wulfkuhle, Julia D; Petricoin, Emanuel F; Osada, Takuya; Yang, Xiao-Yi; Hartman, Zachary C; Clay, Timothy M; Blackwell, Kimberly L; Lyerly, Herbert K; Spector, Neil L.
Affiliation
  • Xia W; Duke Comprehensive Cancer Research Center, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. Wenle.Xia@duke.edu
Mol Cancer Ther ; 10(8): 1367-74, 2011 Aug.
Article in En | MEDLINE | ID: mdl-21673090

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2011 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2011 Type: Article Affiliation country: United States